RCUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Arcus Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$22.14+0.02 (+0.09%)
Close on Oct 19, 2026
- Market cap
- $2.79B
- P/E (TTM)
- –
- Dividend yield
- –
Arcus Biosciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| License and development services | $221.00M | $222.00M | $80.00M | – | – | – | – | – | 89.5% | -0.5% |
| Other collaboration | $26.00M | $36.00M | $37.00M | $38.00M | $38.00M | $23.00M | $7.00M | – | 10.5% | -27.8% |
| Taiho Collaboration Agreement | – | – | – | – | – | $7.00M | $7.00M | $5.35M | – | – |
| Collaboration | – | – | – | – | – | $22.42M | $7.00M | $5.35M | – | – |
| License | – | – | – | – | $343.84M | $55.10M | $8.00M | $3.00M | – | – |
| Taiho License to Etrumadenant | – | – | – | – | – | – | – | $3.00M | – | – |
| Taiho License to Zimberelimab | – | – | – | – | – | – | $8.00M | – | – | – |
| Taiho Access Rights | – | – | – | – | $7.00M | $7.00M | $7.00M | – | – | – |
| Gilead Access Rights | – | – | – | – | $30.91M | $15.42M | – | – | – | – |
| Gilead License To Zimberelimab | – | – | – | – | – | $55.10M | – | – | – | – |
| License and Development Services Revenue | – | $222.00M | $80.00M | $74.00M | $345.00M | $55.00M | – | – | – | – |
| Access rights | – | – | $33.00M | $33.00M | $31.00M | $16.00M | – | – | – | – |
| Gilead Collaboration, License to Zimberelimab | – | – | – | – | – | $55.00M | – | – | – | – |
| Access rights | – | – | $0 | $5.00M | $7.00M | $7.00M | – | – | – | – |
| Gilead License to Domvanalimab | – | – | – | – | $328.84M | – | – | – | – | – |
| Development Services for all Gilead Programs | – | – | – | – | $1.14M | – | – | – | – | – |
| Taiho License to Domvanalimab | – | – | – | – | $15.00M | – | – | – | – | – |
| License and R&D services | – | – | $79.00M | $74.00M | $1.00M | – | – | – | – | – |
| License to domvanalimab | – | – | $0 | $0 | $329.00M | – | – | – | – | – |
| License to domvanalimab | – | – | $0 | $0 | $15.00M | – | – | – | – | – |
| R&D services | – | – | $5.00M | $0 | $0 | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Arcus Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.